NISSAN
11.2.2020 18:50:08 CET | Business Wire | Press release
Nissan comes to the rescue of frazzled parents across Europe with a guilt-free solution for those who heavily rely on the magical effects of dream driving to gently lull their children to sleep.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200211005864/en/
Introducing, the Nissan LEAF Dream Drive – the world’s first zero-emission lullaby, dreamt up by Nissan engineers in collaboration with Sound Designer and Sleep Coach, Tom Middleton. This sleep album for babies mimics the peaceful sound frequencies of a humming combustion engine – trusted to put children to sleep, at no CO2 emission cost.
New research finds parents across Europe are frustratingly sleep-deprived. The majority of parents (65%), with a child aged two and under, is surviving on less than five hours of sleep a night, with 60%v admitting they resort to dream drivingvi their children to sleep and over half (57%) doing it at least once a week.
When looking at why parents put their faith in this method, Nissan discovered that 70%vii of parents put their trust in the power of the vehicle’s movement, when in fact it is the soothing sound frequencies of an internal combustion engine (ICE) that is the biggest contributor to a child falling asleep in the car.
According to expert, Paul Speed-Andrews, Noise and Vibration Development Manager at Nissan, “An EV like the Nissan LEAF is a better choice for dream driving; although we are aware that the quiet soundscape might not be as effective as ICE cars. Combustion engines transmit a sound frequency, a combination of white, pink and brown noise varied in tone – creating an orchestral soundscape that is especially soothing and comforting to children.”
Frequent dream driving in a combustion engine leads to an increase in carbon footprint; with parents emitting up to 70,000g of CO2 emissionsviii every year. However, 70% of European parents agree an EV would reduce their guilt around dream driving and want to become better environmental role models for their children.
To offer a solution, Nissan has collaborated with renowned Sound Designer and Sleep Coach, Tom Middleton, to create Nissan LEAF Dream Drive – the first zero-emission lullaby, the kryptonite album for angry babies, contains five, three-minute tracks that work in harmony with the advanced in-car technology available within the all-electric LEAF.
“Nissan’s zero-emission lullaby combines early auditory development research with creative strategy and is inspired by the audible and inaudible sounds of the Nissan LEAF,” says Sound Designer, Tom Middleton. “Together with Nissan, we are finding innovative, health and safety-conscious ways to apply functional sound within EVs that goes beyond the vehicle itself, effectively inspiring a new generation of purpose-driven, human-first car design and functionality.”
Tom Middleton added: “It is the world’s first collaboration with a car as featured artist. In addition to the combustion engine frequencies that only children can hear – which help lull them to sleep – every sound you can hear comes from building an orchestra of sounds and rhythms from interior and exterior recordings of the LEAF.”
Dream driving in a Nissan LEAF could also help make the experience more relaxing for parents. Zero exhaust emissions and the car’s e-Pedal functionality aid in a smoother ride, allowing seamless driving and braking with a single pedal.
In addition, ProPILOT Assist significantly reduces driver stress and makes dream driving at night more comfortable and safer. It helps parents maintain a steady speed, keep a safe distance away from other cars and ensure they stay in lane.
“The Nissan Dream Drive depicts the future of using sound and other sensory elements to improve people’s lives, bringing together multisensory science, immersive technologies and sound design to explore new wellness-led opportunities within mobility.,” said Ari Peralta, interdisciplinary researcher who helped provide research insight on the project. “Our first – the Nissan LEAF Dream Drive, crafted in collaboration with Nissan – is set to help sleep-deprived parents across Europe.”
Parents can connect their smartphone to their Nissan LEAF through Android Auto and Apple CarPlay, to enjoy the lullaby available on platforms like Apple Music, Spotify, SoundCloud, YouTube and Deezer.
Listen to the zero-emission lullaby on the following streaming platforms: https://lifetracks.lnk.to/NissanLEAFDreamDrive
Learn more about 100% Electric Nissan LEAF on: https://www.nissan.co.uk/vehicles/new-vehicles/leaf.html
### ENDS ###
About Nissan in Europe
Nissan has one of the most comprehensive European presences of any overseas manufacturer, employing more than 16,000 staff across locally based design, research & development, manufacturing, logistics and sales & marketing operations. In 2018, Nissan plants in the UK, Spain and Russia produced about 600,000 vehicles including award-winning crossovers, commercial vehicles and the Nissan LEAF, Europe’s most selling electric vehicle in 2018. Pursuing a goal of zero emissions and zero fatalities on the road, Nissan is leading the field with its vision of Intelligent Mobility. Designed to guide Nissan’s product and technology pipeline, this 360 degree approach to the future of mobility will anchor critical company decisions around how cars are powered, how cars are driven, and how cars integrate into society.
About Nissan Motor Co., Ltd.
Nissan is a global full-line vehicle manufacturer that sells more than 60 models under the Nissan, INFINITI and Datsun brands. In fiscal year 2018, the company sold 5.52 million vehicles globally, generating revenue of 11.6 trillion yen. Nissan’s global headquarters in Yokohama, Japan, manages operations in six regions: Asia & Oceania; Africa, the Middle East & India; China; Europe; Latin America; and North America. Nissan has partnered with French manufacturer Renault since 1999 and acquired a 34% stake in Mitsubishi Motors in 2016. The Renault-Nissan-Mitsubishi alliance sold 10.76 million vehicles combined in calendar year 2018.
For more information about our products, services and commitment to sustainable mobility, visit nissan-global.com . You can also follow us on Facebook , Instagram , Twitter and LinkedIn and see all our latest videos on YouTube .
i Consumer research conducted in November 2019 by Explain the Market and commissioned by Nissan of 7,500 consumers across England, France, Germany, Spain, Italy, Norway and the Netherlands.
ii Dream driving is traditionally a short journey in a car with a combustion engine which helps your child get to sleep.
iii Consumer research conducted in November 2019 by Explain the Market and commissioned by Nissan of 7,500 consumers across England, France, Germany, Spain, Italy, Norway and the Netherlands.
iv This was calculated on the assumption that vehicle travels at an average speed of 48kph per 15-minute dream drive, once a week:
- Average g/km for LEAF-sized, lower medium segment car: 111.5g/km
- Distance travelled in 1 minute, based on the above: 800 metres
- Grams of CO2 emitted in 1 minute, based on the above: 89.2g
-
Amount of CO2
emitted on average, with 780 minutes of dream driving per year: 69,576g (69.576kg)
- Based on 15 minutes of dream driving per week, as per the consumer research findings
v Consumer research conducted in November 2019 by Explain the Market and commissioned by Nissan of 7,500 consumers across England, France, Germany, Spain, Italy, Norway and the Netherlands.
vi Dream driving is traditionally a short journey in a car with a combustion engine which helps your child get to sleep.
vii Consumer research conducted in November 2019 by Explain the Market and commissioned by Nissan of 7,500 consumers across England, France, Germany, Spain, Italy, Norway and the Netherlands.
viii This was calculated on the assumption that vehicle travels at an average speed of 48kph per 15-minute dream drive, once a week:
- Average g/km for LEAF-sized, lower medium segment car: 111.5g/km
- Distance travelled in 1 minute, based on the above: 800 metres
- Grams of CO2 emitted in 1 minute, based on the above: 89.2g
-
Amount of CO2
emitted on average, with 780 minutes of dream driving per year: 69,576g (69.576kg)
- Based on 15 minutes of dream driving per week, as per the consumer research findings
Disclaimer: Whilst unlikely to cause drowsiness in adults, take care whilst driving. Don’t operate heavy machinery or listen to the track whilst submerged in water.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200211005864/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
